Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › Amycretin oral phase 1

Amycretin oral phase 1

Amycretin · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Amycretin
Population
obesity
Phase
1
Participants
144
Duration
12 weeks

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
oral amycretin 50 mgobesity12144——−10.4 % vs −1.2 %
estimand not specified
−0.2 vs +0.0——31.0 vs 8.038.0 vs 0.00.0 vs 0.0—verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (5)
  • oral amycretin 50 mg · nausea · Table 2 (part C/D TEAEs): columns 50 mg (n=16), 2x50 mg (16)
    Nausea 5 (31%) 6 12 (75%) 14 15 (94%) 18 1 (8%)
  • oral amycretin 50 mg · sae · Table 2 (part C/D TEAEs): columns 50 mg (n=16), 2x50 mg (16)
    Serious adverse event Yes 0 0 0 0 1 (6%) 1 0 0
  • oral amycretin 50 mg · vomiting · Table 2 (part C/D TEAEs): columns 50 mg (n=16), 2x50 mg (16)
    Vomiting 6 (38%) 7 9 (56%) 11 10 (63%) 11 0 0
  • oral amycretin 50 mg · hba1c · Table 3
    HbA1c, % Screening, mean (SD) 5·2 (0·4) 5·2 (0·3) 5·4 (0·4) 5·3 (0·4) Day 85, mean (SD) 5·0 (0·3) 5·0 (0·2) 5·1 (0·2) 5·3 (0·3) Change from day 1 to day 85, mean (SD) –0·2 (0·2) –0·3 (0·3) –0·3 (0·2) 0·0 (0·2) ETD (95% C
  • oral amycretin 50 mg · weight_unsp · Table 3 (exploratory PD endpoints part C/D), column 1 = Amyc
    Amycretin 50 mg (n=16) Amycretin 2 × 50 mg (n=16) Amycretin 2 × 25 mg (n=16) Placebo* (n=12) Bodyweight, % Change from day 1 to day 85, mean (SD) –10·4 (4·6) –13·1 (4·8) –12·2 (4·5) –1·2 (2·4) Minimum change –2·2 –6·2 –4

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: Amycretin oral phase 1. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/amycretin-oral-phase-1/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.